Dual Biological Therapy for Ulcerative Colitis with Intractable Pyoderma Gangrenosum
Annals of Dermatology
;
: S107-S111, 2023.
Article
in English
| WPRIM
| ID: wpr-976673
ABSTRACT
Pyoderma gangrenosum is one of the dermatological extra-intestinal manifestations of ulcerative colitis (UC). We report a case of a 26-year-old male patient suffering from relapsed UC with a newly developed pyoderma gangrenosum. His skin and intestinal symptoms were intractable to treatment with steroids, immunosuppressants, or a single biological agent such as infliximab, golimumab, or vedolizumab. For the first time in Korea, we report a successful treatment experience of pyoderma gangrenosum in UC using dual biological agents, vedolizumab and infliximab. We strategically targeted each of the intestinal and skin symptoms, with a specific biological agent based on the drug’s mechanism of action.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
English
Journal:
Annals of Dermatology
Year:
2023
Type:
Article
Similar
MEDLINE
...
LILACS
LIS